Skip to main content

Table 2 Comparison of comparative treatment estimates of all models considered in the analysis for viral suppression at 48 weeks as an outcome

From: Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART

Analyses Model DTG vs. EFV
OR (95% CrI)
EFV400 vs. EFV
OR (95% CrI)
DTG vs. EFV400
OR (95% CrI)
Mean change in log-odds Maximum change in log-odds Mean change in proportion Maximum change in proportion
AgD NMA – Unadjusted Fixed 1.85 (1.44, 2.38) 1.15 (0.75, 1.80) 1.61 (0.96, 2.68)
AgD NMA meta-regression – CD4 Fixed 1.87 (1.49, 2.39) 1.16 (0.74, 1.97) 1.62 (0.92, 2.59) 0.033 0.089 0.005 0.015
AgD NMA meta-regression – HIV RNA Fixed 1.85 (1.45, 2.38) 1.15 (0.75, 1.80) 1.61 (0.97, 2.67) 0.001 0.004 0 0
AgD NMA meta-regression – Male Fixed 1.85 (1.45, 2.38) 1.17 (0.73, 1.86) 1.59 (0.93, 2.73) 0.003 0.013 0 0.002
Two-stage AgD NMA – CD4 + HIV RNA + Male Fixed 1.44 (1.12, 1.85) 1.16 (0.75, 1.80) 1.24 (0.75, 2.05) 0.063 0.266 0.01 0.042
Two-stage AgD NMA – CD4 + Male Fixed 1.50 (1.16, 1.93) 1.15 (0.74, 1.81) 1.30 (0.78, 2.16) 0.057 0.221 0.01 0.035
Two-stage AgD NMA – CD4 + HIV RNA Fixed 1.59 (1.23, 2.04) 1.16 (0.74, 1.80) 1.37 (0.82, 2.28) 0.056 0.183 0.009 0.029
Two-stage AgD NMA – HIV RNA + Male Fixed 1.49 (1.16, 1.93) 1.15 (0.74, 1.79) 1.29 (0.78, 2.15) 0.065 0.238 0.009 0.036
Two-stage AgD NMA – HIV RNA Fixed 1.34 (1.04, 1.74) 1.16 (0.74, 1.80) 1.16 (0.70, 1.94) 0.073 0.32 0.012 0.052
Two-stage AgD NMA – CD4 Fixed 1.46 (1.12, 1.91) 1.15 (0.75, 1.79) 1.27 (0.75, 2.11) 0.072 0.253 0.011 0.04
Two-stage AgD NMA – Male Random 1.44 (1.05, 1.99) 1.15 (0.66, 2.04) 1.24 (0.65, 2.39) 0.059 0.299 0.008 0.044
One-stage IPD-AgD NMA – unadjusted Fixed 1.60 (1.26, 2.02) 1.16 (0.75, 1.80) 1.38 (0.84, 2.27) 0.046 0.155 0.014 0.03
One-stage IPD-AgD NMA – CD4 + HIV RNA+ Male Fixed 1.57 (1.23, 2.00) 1.10 (0.70, 1.72) 1.43 (0.86, 2.38) 0.076 0.167 0.052 0.068
One-stage IPD-AgD NMA – CD4 + Male Fixed 1.54 (1.21, 1.95) 1.12 (0.72, 1.75) 1.37 (0.83, 2.26) 0.085 0.187 0.031 0.05
One-stage IPD-AgD NMA – CD4 + HIV RNA Fixed 1.57 (1.24, 2.00) 1.10 (0.70, 1.72) 1.43 (0.85, 2.39) 0.076 0.166 0.03 0.048
One-stage IPD-AgD NMA – HIV RNA + Male Fixed 1.58 (1.24, 2.01) 1.11 (0.71, 1.73) 1.41 (0.85, 2.36) 0.06 0.161 0.054 0.07
One-stage IPD-AgD NMA – CD4 Fixed 1.54 (1.22, 1.95) 1.12 (0.72, 1.75) 1.38 (0.84, 2.26) 0.083 0.181 0.02 0.037
One-stage IPD-AgD NMA – HIV RNA Fixed 1.56 (1.23, 1.97) 1.12 (0.72, 1.75) 1.39 (0.85, 2.27) 0.066 0.174 0.022 0.039
One-stage IPD-AgD NMA – Male Fixed 1.61 (1.27, 2.04) 1.15 (0.74, 1.80) 1.39 (0.83, 2.33) 0.042 0.142 0.008 0.026
Two-stage empirical-priors – CD4 + HIV RNA + Male Fixed 1.60 (1.21, 2.13) 1.08 (0.68, 1.70) 1.48 (0.87, 2.54) 0.102 0.271 0.022 0.049
Two-stage empirical-priors – CD4 + Male Fixed 1.62 (1.24, 2.12) 1.10 (0.70, 1.71) 1.48 (0.88, 2.49) 0.106 0.245 0.023 0.047
Two-stage empirical-priors – CD4 + HIV RNA Fixed 1.65 (1.25, 2.17) 1.09 (0.70, 1.71) 1.50 (0.88, 2.54) 0.087 0.233 0.016 0.042
Two-stage empirical-priors – HIV RNA + Male Fixed 1.58 (1.21, 2.05) 1.10 (0.70, 1.74) 1.43 (0.85, 2.40) 0.092 0.194 0.02 0.039
Two-stage empirical-priors – CD4 Fixed 1.67 (1.28, 2.17) 1.11 (0.71, 1.73) 1.50 (0.90, 2.52) 0.092 0.211 0.019 0.041
Two-stage empirical-priors – HIV RNA Fixed 1.58 (1.24, 2.03) 1.11 (0.71, 1.74) 1.42 (0.85, 2.37) 0.083 0.178 0.021 0.04
Two-stage empirical-priors – Male Fixed 1.58 (1.22, 2.04) 1.14 (0.73, 1.79) 1.38 (0.83, 2.32) 0.056 0.16 0.011 0.028
HMR IPD-AgD NMA – CD4 Fixed 1.34 (0.96, 1.88) 0.94 (0.57, 1.58) 1.42 (0.87, 2.31) 0.226 0.321 0.131 0.148
HMR IPD-AgD NMA – HIV RNA Fixed 2.03 (0.92, 3.96) 1.36 (0.67, 2.57) 1.48 (0.89, 2.46) 0.16 0.221 0.120 0.170
HMR IPD-AgD NMA – Male Fixed 2.20 (1.25, 4.02) 1.48 (0.81, 2.80) 1.48 (0.88, 2.48) 0.258 0.309 0.036 0.050
  1. AgD Aggregate data, IPD Individual patient data, NMA Network meta-analysis, EFV Efavirenz, DTG Dolutegravir, EFV400 Low-dose efavirenz, OR Odds ratio, CrI Credible interval. Note that DTG vs EFV is estimated through a mixed treatment comparison, EFV400 vs EFV by direct comparison and DTG vs EFV400 by an indirect comparison